張思：男，漢族，博士， 血栓中心主任，轉(zhuǎn)化醫(yī)學(xué)中心主任。碩導(dǎo)。學(xué)科專業(yè)：腫瘤學(xué)；內(nèi)科學(xué)研究方向：1. 消化腫瘤疾病機(jī)制和治療靶點(diǎn)臨床轉(zhuǎn)化；2. 心血管疾病機(jī)制和臨床轉(zhuǎn)化；3. 遺傳性疾病發(fā)病和治療靶點(diǎn)臨床轉(zhuǎn)化。地址郵編;上海市徐匯區(qū)東安路 130號(hào);電子郵箱zhangsi@fudan.edu.cn

張思，安徽理工大學(xué)醫(yī)學(xué)院特聘教授，上海交通大學(xué)附屬新華醫(yī)院特聘教授，美國德克薩斯醫(yī)學(xué)中心訪問學(xué)者，復(fù)旦大學(xué)上海醫(yī)學(xué)院教授，博士生導(dǎo)師。任國際學(xué)術(shù)刊物Frontiers in Cell and Developmental Biology （SCI，影響因子6）副主編， Frontiers in Pharmacology（SCI，影響因子5.9），F(xiàn)rontiers in Immunology（SCI，影響因子8.7）客座副主編，International Journal of Molecular Sciences（SCI，影響因子6）客座編輯，血栓中心主任，腫瘤課題組長(zhǎng)，中國腫瘤微創(chuàng)聯(lián)盟精準(zhǔn)醫(yī)學(xué)專委會(huì)委員，中國康復(fù)醫(yī)學(xué)會(huì)議皮膚腫瘤學(xué)組委員。發(fā)表SCI論文60余篇，引用1000余次，H-Index為21，近年以第一或通訊作者發(fā)表10分以上論文10篇，其中20分以上6篇。包括Web of Science高引用率熱點(diǎn)論文，以及Faculty 1000推薦論文。獲中華醫(yī)學(xué)會(huì)科技三等獎(jiǎng)、上海市科技進(jìn)步二等獎(jiǎng)、上海市醫(yī)學(xué)科技獎(jiǎng)一等獎(jiǎng)等獎(jiǎng)勵(lì)，以項(xiàng)目負(fù)責(zé)人負(fù)責(zé)國家自然科學(xué)基金項(xiàng)目4項(xiàng)和上海市項(xiàng)目等資助4項(xiàng)。授權(quán)腫瘤治療藥物，心血管藥物中國發(fā)明專利6項(xiàng)和國際PCT專利2項(xiàng)。國家自然科學(xué)基金委評(píng)審專家，科技部項(xiàng)評(píng)審專家，Science Immunology等國際知名刊物審稿人。

指導(dǎo)學(xué)生情況

培養(yǎng)博士，碩士研究生20余人，培養(yǎng)學(xué)生已獲國家自然科學(xué)基金青年項(xiàng)目，面上項(xiàng)目，上海市優(yōu)秀畢業(yè)生，上海市醫(yī)學(xué)楊帆計(jì)劃，中山醫(yī)院骨干人才計(jì)劃，等項(xiàng)目多項(xiàng)，在各大醫(yī)院工作。

導(dǎo)師寄語

快樂學(xué)習(xí)，健康成長(zhǎng)，保持責(zé)任，做有用的人，投身健康事業(yè)

1. 消化腫瘤疾病機(jī)制和治療靶點(diǎn)臨床轉(zhuǎn)化；2. 心血管疾病機(jī)制和臨床轉(zhuǎn)化；3. 遺傳性疾病發(fā)病和治療靶點(diǎn)臨床轉(zhuǎn)化。地址郵編;上海市徐匯區(qū)東安路 130號(hào);電子郵箱zhangsi@fudan.edu.cn 

國家級(jí)科研項(xiàng)目：

2023，國家自然科學(xué)基金面上項(xiàng)目，“國家自然科學(xué)基金面上項(xiàng)目u-成孔效應(yīng)蛋白Gasdermin E在血小板中的表達(dá)和功能研究”，主持

2021，上海市自然科學(xué)基金面上項(xiàng)目，“Baz蛋白調(diào)控血小板細(xì)胞骨架重構(gòu)和活化的研究”，主持

2018，國家自然科學(xué)基金面上項(xiàng)目，“細(xì)胞極性蛋白Pard3在血小板中的表達(dá)和功能研究”，主持

2016，國家自然科學(xué)基金面上項(xiàng)目，“核受體FXR在無核血小板中的表達(dá)和功能”，主持

2012，國家自然科學(xué)基金青年項(xiàng)目，“P2Y12 受體激活抗血小板凋亡的機(jī)制研究”，主持

代表性論著：

1.Huajie Xu, Jiaojiao Zheng,; Xin Zhao, Qi Zhou, Bing Fan, Hongyi Wu, Si Zhang通訊）*,; Junbo Ge *. Inactivated whole-virion SARS-CoV-2 vaccines and long-term clinical outcomes in 1 patients with coronary atherosclerosis disease in China: a prospective cohort study. Cardiovascular Research. 2023. . IF=14

2.Fuing Chen#, Cheng Ni#, Xiaoxiao Wang#, Ruhong Cheng#, Chaolan Pan#, Yumeng Wang, Jianying Liang, Jia Zhang, Jinke Cheng, Y Eugene Chin, Yi Zhou, Zhen Wang, Yiran Guo, She Chen, Stephanie Htun, Erin F. Mathes, Alejandra G. de Alba Campomanes, Anne M. Slavotinek, Si Zhang（通訊）*, Ming Li1,*and Zhirong Yao*. S1P Defects Cause a New Entity of Cataract, Alopecia, Oral Mucosal Disorder, and Psoriasis-like Syndrome. Embo Molecular Medicine. 2022; e14904. doi: 10.15252/emmm.202114904. IF=14

3.Wang, Biyun; Zhao, Yannan; Li, Yi; Xu, Yingying; Chen, Yun; Jiang, Qiuyu; Yao, Dingjin; Z hang, Li; Hu, Xichun; Fu, Chaowei*; Zhang, Si（通訊）*; Chen, She* ; A plasma SNORD33 signature predicts pla tinum beneft in metastatic triple-negative breast cancer patients, Molecular Cancer, 2022, 21(1): 22. IF=40

4.Chen, Yufei; Fu, Wanrong; Zheng, Yunbo; Yang, Jing; Liu, Yangyang; Qi, Zhiyong; Wu, Meili ng; Fan, Zhichao; Yin, Kanhua; Chen, Yunfeng; Gao, Wen; Ding, Zhongren; Dong, Jianzeng; Li, Qi*; Zhang, Si（通訊）*; Hu, Liang* ; Galectin 3 enhances platelet aggregation and thrombosis via Dectin-1 activa tion: a translational study, European Heart Journal, 2022, 00: 1-19. IF=30

5.Yi Zhou, Liang Hu, Wenqing Tang, Dongping Li, Lijie Ma, Hongchun Liu, Shuncai Zhang, Xiaojie Zhang, Ling Dong, Xizhong Shen, She Chen*, Ruyi Xue* and Si Zhang(通訊)*. Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism. Journal of hematology & oncology. 2021 14(8) 1-19. IF=28

6.Xinyi Liu, Yanjie Chen, Si Zhang （通訊）*& Ling Dong. Gut microbiota-mediated immunomodulation in tumor. Journal of Experimental & Clinical Cancer Research, 2021, 40(1): 1-20. IF=11

7.Si Zhang*(通訊), Yangyang Liu, Xiaofang Wang, Li Yang, Haishan Li, Yuyan Wang, Mengduan Liu, Xiaoyan Zhao, Youhua Xie, Yan Yang, Shenghui Zhang, Zhichao Fan, Jianzeng Dong, Zhenghong Yuan, Zhongren Ding, Yi Zhang* & Liang Hu*. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. Journal of hematology & oncology, 2020，13(1), 1-22. SCI; IF=28

8.Pingping Dong，Xiaoxiao Wang，Longzi Liu，Wenqing Tang，Lijie Ma，Wenjiao Zeng，Shaoyang Sun，Li Zhang，Ningping Zhang，Xizhong Shen，Harry L.A. Janssen，Ling Dong*，Si Zhang*（通訊）， She Chen* . Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma. Journal of Hepatology. 2020, 73(6), 1446-1459. IF=32

9.Si Zhang，Shenghui Zhang, Liang Hu, Lili Zhai, Ruyi Xue, Jianqin Ye, Leilei Chen,Guanjun Cheng, Jozef Mruk， SP Kunapuli, Zhongren Ding. Nucleotide-Binding Oligomerization Domain 2 Receptor Is Expressed in Platelets and Enhances Platelet Activation and Thrombosis. Circulation, 2015. 131(13):1160-70. IF=30

10.Liu, Xijun; Xue, Ruyi; Yang, Caiting; Gu, Jianxin; Chen, She*; Zhang, Si（通訊）* ; Cholestasis-ind uced bile acid elevates estrogen level via farnesoid X receptor-mediated suppression of the estro gen sulfotransferase SULT1E1. Journal of Biological Chemistry, 2018, 293(33): 12759-12769

11.Cai, Yu; Huang, Guanqun; Ma, Lijie; Dong, Ling; Chen, She; Shen, Xizhong; Zhang, Shuncai; Xue, Ruyi*; Sun, Deqiang*; Zhang, Si （通訊）*; Smurf2, an E3 ubiquitin ligase, interacts with PDE4B and att enuates liver fibrosis through miR-132 mediated CTGF inhibition. Biochimica et Biophysica Acta-Molecular Cell Research, 2018, 1865(2): 297-308

在研項(xiàng)目

2023-2026 國家自然科學(xué)基金面上項(xiàng)目，“國家自然科學(xué)基金面上項(xiàng)目u-成孔效應(yīng)蛋白Gasdermin E在血小板中的表達(dá)和功能研究”，主持

2021-2024上海市自然科學(xué)基金面上項(xiàng)目，“Baz蛋白調(diào)控血小板細(xì)胞骨架重構(gòu)和活化的研究”，主持